Advertisement

Inpharma Weekly

, Volume 1030, Issue 1, pp 9–10 | Cite as

Establishing a therapeutic niche for tirapazamine

  • Robert Short
Newsletter Article

Abstract

Tirapazamine is a new bioreductive agent that has exhibited cytotoxic activity against advanced tumours. Current studies are investigating how this agent can be used to its maximum potential. A combination of cisplatin and tirapazamine appears to be effective in chemotherapy-naive non-small cell lung cancer (NSCLC), leading to a greater response rate than that associated with cisplatin monotherapy. However, the combination has shown little promise in platinum-resistant tumours in phase II trials to date. Data from these studies were presented at the 9th National Cancer Institute (NCI) - European Organisation for the Research and Treatment of Cancer (EORTC) joint symposium [ Amsterdam, The Netherlands; March 1996 ].

Keywords

Ovarian Cancer Muscle Cramp Choroidal Melanoma Cutaneous Primary Melanoma Tirapazamine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Adis International Ltd 1996

Authors and Affiliations

  • Robert Short

There are no affiliations available

Personalised recommendations